Fresh off positive Nuplazid data, Acadia adds new clinical drug from Vanderbilt in milestone-heavy deal
Acadia Pharma’s primary strategy over the last few years has been to get its controversial Parkinson’s drug approved for other diseases, including depression and schizophrenia …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
